A000227 Stock Overview
Develops and markets pharmaceutical products. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Yuyu Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩9,590.00 |
52 Week High | ₩15,970.00 |
52 Week Low | ₩9,030.00 |
Beta | 0.51 |
1 Month Change | -5.52% |
3 Month Change | -9.36% |
1 Year Change | -20.81% |
3 Year Change | -49.53% |
5 Year Change | 2.02% |
Change since IPO | 324.34% |
Recent News & Updates
Recent updates
Shareholder Returns
A000227 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | -1.0% | 1.8% | -2.1% |
1Y | -20.8% | 4.3% | -9.0% |
Return vs Industry: A000227 underperformed the KR Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: A000227 underperformed the KR Market which returned -9% over the past year.
Price Volatility
A000227 volatility | |
---|---|
A000227 Average Weekly Movement | 10.0% |
Pharmaceuticals Industry Average Movement | 5.6% |
Market Average Movement | 6.6% |
10% most volatile stocks in KR Market | 12.7% |
10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A000227's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A000227's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 253 | Robert Yu | www.yuyu.co.kr |
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Yuyu Pharma, Inc. Fundamentals Summary
A000227 fundamental statistics | |
---|---|
Market cap | ₩73.79b |
Earnings (TTM) | ₩8.56b |
Revenue (TTM) | ₩134.79b |
8.6x
P/E Ratio0.5x
P/S RatioIs A000227 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A000227 income statement (TTM) | |
---|---|
Revenue | ₩134.79b |
Cost of Revenue | ₩83.69b |
Gross Profit | ₩51.10b |
Other Expenses | ₩42.55b |
Earnings | ₩8.56b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 528.76 |
Gross Margin | 37.91% |
Net Profit Margin | 6.35% |
Debt/Equity Ratio | 26.4% |
How did A000227 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 02:46 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yuyu Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |